|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Stock Picks for Healthy Returns
MNTA
|
|
|
<> Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X. Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one. >...
|
UpDown Virtual Investing: Earn Real Money with Zero Risk
MNTA
|
|
|
<> <> The ultimate risk/reward trade for virtual investing – its is free and easy to register at the UpDown and users can earn real money at the site in two ways. The first is by beating the market (S&P 500 Index) on a monthly basis and the second is by referring investors. However, the referral system is designed to encourage legitamte referals only by basing the payment on how much the referred person earns on the site. So, if you refer someone who earns $100, you will receive 10% or $10 as a referral bo>>...
|
Teva Beats on Profits: A Biogeneric Boon in '09?
MNTA
|
|
|
<> <> Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou>>...
|
A Bullish Outlook for Generic Drugs After Election
MNTA
|
|
|
<> In addition to the favorable underlying trends I wrote about previously for the generic drug industry, both presidential candidates are bullish on the industry with the following excerpts taken directly from their websites: Senator Obama : Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs and taking on drug companies that block cheaper generic medicines from the market. Senator McCain : R>...
|
Biotech Blues: Four Stocks on Sale with Hope
MNTA
|
|
|
<> The following group of biotech companies have market caps of at least $300M with a one year stock price change that is below the iShares Nasdaq Biotech ETF (IBB) loss of 21.8% (Source: Google Finance, 10/25/08) with potential upside catalysts over the next year. Alnylam Pharma (ALNY): $872M, -31.6% Biogen Idec (BIIB): $12B, -48.4% BioMarin Pharma (BMRN): $1.7B, -33% Momenta Pharma (MNTA): $348M, -23.4% Momenta and Novartis (NVS) expect to launch a generic version (M-Enoxaparin) of the injectable>...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on MNTA |
Visit streetinsider.com
More Resources
|